Clinical Trial Update: A Study Of Two Dual PI3K/mTOR Inhibitors, PF-04691502 And PF-05212384 In Patients With Recurrent Endometrial Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial of two dual PI3K/mTOR inhibitors in recurrent endometrial cancer was terminated; results were posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Cancer

Drugs mentioned

• PF-04691502
• PF-05212384

Snippet

Sponsor: Pfizer | Conditions: Endometrial Neoplasms | Phase 2 | Status: TERMINATED | Results posted: 2015-05-19